Corrections: Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies (The Lancet Infectious Diseases (2018)(S1473309918301105)(10.1016/S1473-3099(18)30110-5));Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

The Lancet Infectious Diseases

Volumn 18, Issue 7, 2018, Pages e183-e198

  Tiberi, Simon ^a   du Plessis, Nelita ^b   Walzl, Gerhard ^b   Vjecha, Michael J ^c   Rao, Martin ^d,e   Ntoumi, Francine ^f   Mfinanga, Sayoki ^g   Kapata, Nathan ⁱ   Mwaba, Peter ^h   McHugh, Timothy D ^l   Ippolito, Giuseppe ^j   Migliori, Giovanni Battista ^k   Maeurer, Markus J ^d,e   Zumla, Alimuddin ^l,m  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CHAMPALIMAUD FOUNDATION   (Portugal)

^e KRANKENHAUS NORDWEST   (Germany)

^f Universite M Ngouabi   (Congo)

^g NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^h UNIVERSITY OF ZAMBIA   (Zambia)

ⁱ MINISTRY OF HEALTH   (Zambia)

^j NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BEDAQUILINE; BIOLOGICAL PRODUCT; BTZ 043; CAPREOMYCIN; CLOFAZIMINE; CONTEZOLID; CYCLOSERINE; DELAMANID; DELPAZOLID; ETHIONAMIDE; GATIFLOXACIN; GSK 070; GSK 3036656; KANAMYCIN; LEVOFLOXACIN; MACOZINONE; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NEW DRUG; OPC 167832; PRETOMANID; STREPTOMYCIN; SUTEZOLID; TBA 7371; TBI 166; TELACEBEC; TERIZIDONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG REPOSITIONING; DRUG RESEARCH; DRUG SENSITIVITY; DRUG WITHDRAWAL; HUMAN; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MEDICATION COMPLIANCE; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SKIN DISCOLORATION; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; COMBINATION DRUG THERAPY; DRUG DEVELOPMENT; DRUG EFFECT; MULTIMODALITY CANCER THERAPY; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; DRUG DEVELOPMENT; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 85044296948     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30283-4     Document Type: Erratum

References (147)

1. WHO. Global tuberculosis report, 2017. 2017, World Health Organization, Geneva.
2. Ahmad Khan, F, Salim, MAH, du Cros, P, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J, 50, 2017, 1700061.
3. Mitnick, CD, White, RA, Lu, C, et al. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J 48 (2016), 1160–1170.
4. Dheda, K, Limberis, JD, Pietersen, E, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med 5 (2017), 269–281.
5. Günther, G, Lange, C, Alexandru, S, et al. Treatment outcomes in multidrug-resistant tuberculosis. N Engl J Med 375 (2016), 1103–1105.
6. Zignol, M, Dean, AS, Falzon, D, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med 375 (2016), 1081–1089.
7. Zumla, A, Abubakar, I, Clinical trial research in focus: overcoming barriers in MDR-TB clinical trials. Lancet Respir Med 5 (2017), 247–248.
8. Wallis, RS, Maeurer, M, Mwaba, P, et al. Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies and biomarkers. Lancet Infect Dis 16 (2016), e34–e46.
9. Zuur, MA, Akkerman, OW, Davies Forsman, L, et al. Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. Eur Respir J 48 (2016), 1230–1233.
10. Alffenaar, JC, Migliori, GB, Gumbo, T, Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. Lancet Infect Dis, 17, 2017, 898.
11. Nahid, P, Droman, E, Alipanah, N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 63 (2016), 853–867.
12. Lienhardt, C, Nahid, P, Rich, ML, et al. Target regimen profiles for treatment of tuberculosis: a WHO document. Eur Respir J, 49, 2017, 1602352.
13. Dheda, K, Gumbo, T, Maartens, G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 5 (2017), 291–360.
14. Lienhardt, C, Lönnroth, K, Menzies, D, et al. Translational research for tuberculosis elimination: priorities, challenges, and actions. PLoS Med, 13, 2016, e1001965.
15. Sulis, G, Centis, R, Sotgiu, G, et al. Recent developments in the diagnosis and management of tuberculosis. NPJ Prim Care Respir Med, 26, 2016, 16078.
16. Heemskerk, AD, Bang, ND, Mai, NT, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med 374 (2016), 124–134.
17. Stop TB Partnership's Working Group on New TB Drugs. Clinical pipeline. http://www.newtbdrugs.org/pipeline/clinical (accessed Feb 20, 2018).
18. Lessem, E, Low, M, The tuberculosis treatment pipeline. Claydon, P, Collins, S, Frick, M, et al. (eds.) 2016 Pipeline report: HIV and TB, Drugs, diagnostics, vaccines, preventive technologies, cure research, and immune-based and gene therapies in development, 2016, Treatment Action Group, New York, NY, 129–142.
19. Working Group on New TB Drugs. Press release from Infectex and Sequella on SQ-109 clinical trial in Russia. http://www.newtbdrugs.org/news/press-release-infectex-and-sequella-sq-109-clinical-trial-russia (accessed Dec 11, 2017).
20. TB Alliance. Phase 1 clinical trial of TB drug candidate TBA-354 discontinued. http://www.tballiance.org/news/phase-1-clinical-trial-tb-drug-candidate-tba-354-discontinued (accessed Oct 21, 2017).
21. Aseffa, A, Chukwu, JN, Vahedi, M, et al. Efficacy and safety of ‘fixed dose’ versus ‘loose’ drug regimens for treatment of pulmonary tuberculosis in two high TB-burden African countries: a randomized controlled trial. PLoS One, 11, 2016, e0157434.
22. WHO. New fixed-dose combinations for the treatment of TB in children. http://www.who.int/tb/FDC_Factsheet.pdf (accessed Oct 20, 2017).
23. Seddon, JA, Schaaf, HS, Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis. Pneumonia (Nathan), 8, 2016, 20.
24. Wu, J, Liao, S, Sun, Z, Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. Ann Clin Microbiol Antimicrob, 16, 2017, 67.
25. Amagon, K, Awodele, O, Akindele, AJ, Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients. Pharmacol Res Perspect, 5, 2017, e00360.
26. Jindani, A, Borgulya, G, de Patino, IW, et al. A randomised phase 2 trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. Int J Tuberc Lung Dis 20 (2016), 832–838.
27. Boeree, MJ, Heinrich, N, Aarnoutse, R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomized controlled trial. Lancet Infect Dis 17 (2017), 39–49.
28. Papineni, P, Phillips, P, Lu, Q, Cheung, YB, Nunn, A, Paton, N, TRUNCATE-TB: an innovative trial design for drug-sensitive tuberculosis. Int J Infect Dis, 45(suppl 1), 2016, 404.
29. Naidoo, A, Naidoo, K, McIlleron, H, Essack, S, Padayatchi, N, A review of moxifloxacin for the treatment of drug-susceptible tuberculosis. J Clin Pharmacol 57 (2017), 1369–1386.
30. Olliaro, PL, Merle, C, Mthiyane, T, et al. Effects on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 61 (2017), e01834–e01916.
31. Caminero, JA, Piubello, A, Scardigli, A, Migliori, GB, Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases. Eur Respir J, 50, 2017, 1700648.
32. Tiberi, S, Scardigli, A, Centis, R, et al. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis 56 (2017), 181–184.
33. Falzon, D, Schünemann, HJ, Harausz, E, et al. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J, 49, 2017, 1602308.
34. Caminero, JA, Scardigli, A, Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J 46 (2015), 887–893.
35. Lee, H, Ahn, S, Hwang, NY, et al. Treatment outcomes of rifabutin-containing regimens for rifabutin sensitive multidrug-resistant pulmonary tuberculosis. Int J Infect Dis 65 (2017), 135–141.
36. WHO. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. 2017, World Health Organization, Geneva.
37. DR-TB STAT. Country updates. Updated October. http://drtb-stat.org/country-updates/, 2017 (accessed Dec 9, 2017).
38. Diacon, AH, Pym, A, Grobusch, MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371 (2014), 723–732.
39. Pontali, E, Sotgiu, G, Tiberi, S, D'Ambrosio, L, Centis, R, Migliori, GB, Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J, 50, 2017, 1701462.
40. Borisov, SE, Dheda, K, Enwerem, M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J, 49, 2017, 1700387.
41. WHO. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance (WHO/HTM/TB/2014.23). 2014, World Health Organization, Geneva.
42. Tadolini, M, Garcia-Prats, AJ, D'Ambrosio, L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 48 (2016), 938–943.
43. Skripconoka, V, Danilovits, M, Pehme, L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41 (2013), 1393–1400.
44. McKay, B, New treatments for drug-resistant TB get a boost. Wall Street Journal, Oct 13, 2017 https://www.wsj.com/articles/new-treatments-for-drug-resistant-tb-get-a-boost-1507892402 (accessed Oct 18, 2017).
45. Kuksa, L, Barkane, L, Hittel, N, Gupta, R, Final treatment outcomes of MDR- and XDR-TB patients in Latvia receiving delamanid containing regimens. Eur Respir J, 50, 2017, 1701105.
46. Hafkin, J, Hittel, N, Martin, A, Gupta, R, Early outcomes in MDR and XDR-TB patients treated with delamanid under compassionate use. Eur Respir J, 50, 2017, 1700311.
47. Hafkin J, Frias M, Hesseling A, et al. Pharmacokinetics and safety of delamanid in pediatric MDR-TB patients: ages 6–17 years. Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; 2015: poster A-960.
48. Hafkin J, Frias M, De Leon A, et al. Long-term safety, tolerability and pharmacokinetics of delamanid in pediatric MDR-TB patients, ages 12–17 years. 46th Union World Conference on Lung Health; Cape Town; 2015; 19 (12 suppl 2): S91.
49. Maryandyshev, A, Pontali, E, Tiberi, S, et al. Bedaquiline and delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis. Emerg Infect Dis 23 (2017), 1718–1721.
50. Tadolini, M, Lingtsang, RD, Tiberi, S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 48 (2016), 935–938.
51. AIDS Clinical Trials Group A5343: bedaquiline delamanid study—a trial of the safety, tolerability, and pharmacokinetics of bedaquiline and delamanid, alone and in combination, among participants taking multidrug treatment for drug-resistant pulmonary tuberculosis. https://actgnetwork.org/study/a5343-bedaquiline-delamanid-study (accessed Oct 30, 2017).
52. Dawson R, Harris K, Conradie A, et al. Efficacy of bedaquiline, pretomanid, moxifloxacin and PZA (BPAMZ) against DS- and MDR-TB. Conference on Retroviruses and Opportunistic Infections; Seattle, WA: Feb 13–16, 2017. Abstract 724LB.
53. Lu, Y, Zheng, M, Wang, B, et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother 55 (2011), 5185–5193.
54. Dalcolmo, M, Gayoso, R, Sotgiu, G, et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J, 49, 2017, 1602445.
55. Hartkoorn, RC, Uplekar, S, Cole, ST, Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58 (2014), 2979–2981.
56. Sotgiu, G, D'Ambrosio, L, Centis, R, et al. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci, 17, 2016, 373.
57. Tiberi, S, Payen, MC, Sotgiu, G, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 47 (2016), 1235–1243.
58. Diacon, AH, van der Merwe, L, Barnard, M, et al. β-lactams against tuberculosis—new trick for an old dog?. N Engl J Med 375 (2016), 393–394.
59. Srivastava, S, Deshpande, D, Pasipanodya, J, Nuermberger, E, Swaminathan, S, Gumbo, T, Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: goldilocks. Clin Infect Dis 63:suppl 3 (2016), S102–S109.
60. Deshpande, D, Srivastava, S, Nuermberger, E, Pasipanodya, JG, Swaminathan, S, Gumbo, T, A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME path on the Milky Way. Clin Infect Dis 63:suppl 3 (2016), S95–S101.
61. Tiberi, S, Sanz, MG, Millar, M, The need for global regulation of antibiotics: the case of a generic oral penem. Clin Infect Dis 62 (2016), 1466–1467.
62. Srivastava, S, van Rijn, SP, Wessels, AM, Alffenaar, JW, Gumbo, T, Susceptibility testing of antibiotics that degrade faster than the doubling time of slow-growing mycobacteria: ertapenem sterilizing effect versus mycobacterium tuberculosis. Antimicrob Agents Chemother 60 (2016), 3193–3195.
63. Tiberi, S, D'Ambrosio, L, De Lorenzo, S, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 47 (2016), 333–336.
64. Deshpande, D, Srivastava, S, Chapagain, M, et al. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. Sci Adv, 3, 2017, e1701102.
65. Sotgiu, G, Pontali, E, Migliori, GB, Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 45 (2015), 25–29.
66. Gumbo, T, Angulo-Barturen, I, Ferrer-Bazaga, S, Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 211:suppl 3 (2015), S96–S106.
67. van Rijn, SP, Srivastava, S, Wessels, MA, van Soolingen, D, Alffenaar, JC, Gumbo, T, Sterilizing effect of ertapenem-clavulanate in a hollow-fiber model of tuberculosis and implications on clinical dosing. Antimicrob Agents Chemother 61 (2017), e02039–e02116.
68. Srivastava, S, Magombedze, G, Koeuth, T, et al. Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrob Agents Chemother 61 (2017), e00751–e00817.
69. Van Deun, A, Maug, A, Salim, A, et al. Short, highly effective, and inexpensive standardised, treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182 (2010), 684–692.
70. Aung, K, Van Deun, A, Declerq, E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18 (2014), 1180–1187.
71. Piubello, A, Harouna, S, Souleymane, MB, et al. High cure rate with standardized short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 18 (2014), 1188–1194.
72. van der Werf, MJ, Ködmön, C, Catchpole, M, Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe. Eur Respir J, 49, 2017, 1700463.
73. Yassin, MA, Jaramillo, E, Wandwalo, E, et al. Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: txpeated. Eur Respir J, 49, 2017, 1700081.
74. Barry, PM, Lowenthal, P, True, L, et al. Benefit of the shorter MDR TB treatment regimen in california and modified eligibility criteria. Am J Respir Crit Care Med 196 (2017), 1488–1489.
75. Chee, CBE, KhinMar, KW, Sng, LH, et al. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from south-east Asia eligible?. Eur Respir J, 50, 2017, 1700753.
76. Medical Research Council Clinical Trials Unit. Preliminary results from STREAM trial provide insight into shorter treatment for multidrug-resistant tuberculosis. http://www.ctu.mrc.ac.uk/news/2017/preliminary_results_from_stream_trial_provide_insight_into_shorter_treatment_for_multidrug_resistant_tuberculosis (accessed Oct 27, 2017).
77. Conradie F, Diacon AH, Everitt D, et al. The NIX-TB trial of pretomanid, bedaquiline and linezolid to treat XDR-TB. Conference on Retroviruses and Opportunistic Infections; Seattle, WA; Feb 13–16, 2017. Abstract 80LB.
78. Huerga, H, Moreto, L, Programa endTB: experiencia de MSF con los nuevos fármacos para la TB (Delamanid y Bedaquilina). MESA: Cooperacion internacional. Rev Enf Emerg 16 (2017), 125–176.
79. Sterling, TR, Villarino, ME, Borisov, AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365 (2011), 2155–2166.
80. WHO. Guidelines on the management of latent tuberculosis infection. 2015, World Health Organization, Geneva.
81. Zumla, A, Chakaya, J, Hoelscher, M, et al. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov 14 (2015), 511–512.
82. Gupta, A, Meena, J, Sharma, D, et al. Inhalable particles for “pincer therapeutics” targeting nitazoxanide as bactericidal and host-directed agent to macrophages in a mouse model of tuberculosis. Mol Pharm 13 (2016), 3247–3255.
83. Singhal, A, Jie, L, Kumar, P, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med, 6, 2014, 263ra159.
84. Ventimiglia, LN, Alonso, MA, Biogenesis and function of T cell-derived exosomes. Front Cell Dev Biol, 4, 2016, 84.
85. Colombo, M, Raposo, G, Thery, C, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30 (2014), 255–289.
86. Caballero, D, Blackburn, SM, de Pablo, M, Samitier, J, Albertazzi, L, Tumour-vessel-on-a-chip models for drug delivery. Lab Chip 17 (2017), 3760–3771.
87. Cain, DW, Cidlowski, JA, Immune regulation by glucocorticoids. Nat Rev Immunol 17 (2017), 233–247.
88. Critchley, JA, Young, F, Orton, L, Garner, P, Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 13 (2013), 223–237.
89. Bourgi, K, Fiske, C, Sterling, TR, Tuberculosis meningitis. Curr Infect Dis Rep, 19, 2017, 39.
90. Simmons, CP, Thwaites, GE, Quyen, NT, et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol 175 (2005), 579–590.
91. Bilaçeroğlu, S, Perim, K, Büyükşirin, M, Celikten, E, Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Int J Tuberc Lung Dis 3 (1999), 47–54.
92. Wang, J, Wang, H, Yang, X, et al. Glucocorticoids suppress antimicrobial autophagy and nitric oxide production and facilitate survival in macrophages. Sci Rep, 7, 2017, 982.
93. Ricciotti, E, FitzGerald, GA, Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31 (2011), 986–1000.
94. Vilaplana, C, Marzo, E, Tapia, G, Diaz, J, Garcia, V, Cardona, PJ, Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 208 (2013), 199–202.
95. Tonby, K, Wergeland, I, Lieske, NV, Kvale, D, Tasken, K, Dyrhol-Riise, AM, The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection. BMC Infect Dis, 16, 2016, 599.
96. Divangahi, M, Chen, M, Gan, H, et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 10 (2009), 899–906.
97. Mayer-Barber, KD, Andrade, BB, Oland, SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511 (2014), 99–103.
98. Rangel Moreno, J, Estrada García, I, De La Luz García Hernández, M, Aguilar Leon, D, Marquez, R, Hernández Pando, R, The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 106 (2002), 257–266.
99. McCullough, PA, The anti-inflammatory effects of statins. N Engl J Med 345 (2001), 1209–1211.
100. Lai, CC, Lee, MT, Lee, SH, Hsu, WT, Chang, SS, Chen, SC, Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort. Thorax 71 (2016), 646–651.
101. Kang, YA, Choi, NK, Seong, JM, The effects of statin use on the development of tuberculosis among patients with diabetes mellitus. Int J Tuberc Lung Dis 18 (2014), 717–724.
102. Dutta, NK, Bruiners, N, Pinn, ML, et al. Statin adjunctive therapy shortens the duration of TB treatment in mice. J Antimicrob Chemother 71 (2016), 1570–1577.
103. Skerry, C, Pinn, ML, Bruiners, N, Pine, R, Gennaro, ML, Karakousis, PC, Simvastatin increases the in-vivo activity of the first-line tuberculosis regimen. J Antimicrob Chemother 69 (2014), 2453–2457.
104. Boswell-Smith, V, Spina, D, Page, CP, Phosphodiesterase inhibitors. Br J Pharmacol 147 (2006), S252–S257.
105. Serafini, P, Meckel, K, Kelso, M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203 (2006), 2691–2702.
106. Maiga, M, Ammerman, NC, Maiga, MC, et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 208 (2013), 512–519.
107. Subbian, S, Tsenova, L, Holloway, J, et al. Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model. EBioMedicine 4 (2016), 104–114.
108. Wu, P, Nielsen, TE, Clausen, MH, FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36 (2015), 422–439.
109. Bruns, H, Stegelmann, F, Fabri, M, et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J Immunol 189 (2012), 4069–4078.
110. Napier, RJ, Norris, BA, Swimm, A, et al. Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog, 11, 2015, e1004770.
111. Blagih, J, Coulombe, F, Vincent, EE, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42 (2015), 41–54.
112. Meng, S, Cao, J, He, Q, et al. Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex. J Biol Chem 290 (2015), 3793–3802.
113. Lee, YJ, Yim, JJ, Han, SK, et al. The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus. Am J Respir Crit Care Med, 195, 2017, A2109.
114. Mahoney, KM, Freeman, GJ, McDermott, DF, The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 37 (2015), 764–782.
115. Dyck, L, Mills, KHG, Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol 47 (2017), 765–779.
116. Jayaraman, P, Jacques, MK, Zhu, C, et al. TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection. PLoS Pathog, 12, 2016, e1005490.
117. Kirman, J, McCoy, K, Hook, S, et al. CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection. Infect Immun 67 (1999), 3786–3792.
118. Jurado, JO, Alvarez, IB, Pasquinelli, V, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 181 (2008), 116–125.
119. Fujita, K, Terashima, T, Mio, T, Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol 11 (2016), 2238–2240.
120. Huang, SJ, Wang, XH, Liu, ZD, Cao, WL, Han, Y, Ma, AG, Vitamin D deficiency and the risk of tuberculosis: a meta-analysis. Drug Des Devel Ther 11 (2016), 91–102.
121. Salahuddin, N, Ali, F, Hasan, Z, et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis'. BMC Infect Dis 19 (2013), 13–22.
122. 3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377 (2011), 242–250.
123. Wallis, RS, Zumla, A, Vitamin D as adjunctive host-directed therapy in tuberculosis: a systematic review. Open Forum Infect Dis, 3, 2016, ofw151.
124. Greenstein, RJ, Su, L, Brown, ST, Vitamins A & D inhibit the growth of mycobacteria in radiometric culture. PLoS One, 7, 2012, e29631.
125. Lawson, L, Thacher, TD, Yassin, MA, et al. Randomized controlled trial of zinc and vitamin A as co-adjuvants for the treatment of pulmonary tuberculosis. Trop Med Int Health 15 (2010), 1481–1490.
126. Aibana, O, Franke, MF, Huang, CC, et al. Impact of vitamin A and carotenoids on the risk of tuberculosis progression. Clin Infect Dis 65 (2017), 900–909.
127. Wheelwright, M, Kim, EW, Inkeles, MS, et al. All-trans retinoic acid-triggered antimicrobial activity against Mycobacterium tuberculosis is dependent on NPC2. J Immunol 192 (2014), 2280–2290.
128. Parida, SK, Axelsson-Robertson, R, Rao, MV, et al. Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med 277 (2015), 388–405.
129. Skrahin, A, Ahmed, RK, Ferrara, G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2 (2014), 108–122.
130. Skrahin, A, Jenkins, HE, Hurevich, H, et al. Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis. J Clin Tuberc Mycobact Dis 4 (2016), 21–27.
131. Nenasheva, T, Nikolaev, A, Diykanov, D, et al. The introduction of mesenchymal stromal cells induces different immunological responses in the lungs of healthy and M tuberculosis infected mice. PLoS One, 12, 2017, e0178983.
132. Knaul, J, Jörg, S, Oberbeck-Mueller, D, et al. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am J Respir Crit Care Med 190 (2014), 1053–1066.
133. du Plessis, N, Loebenberg, L, Kriel, M, et al. Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med 188 (2013), 724–732.
134. El Daker, S, Sacchi, A, Tempestilli, M, et al. Granulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level. PLoS One, 10, 2015, e0123772.
135. Payne, KK, Bear, HD, Manjili, MH, Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncol 10 (2014), 1779–1794.
136. Tamadaho, RSE, Hoerauf, A, Layland, LE, Immunomodulatory effects of myeloid-derived suppressor cells in diseases: role in cancer and infections. Immunobiology, 2017 published online July 4. DOI:10.1016/j.imbio.2017.07.001.
137. Tobin, RP, Davis, D, Jordan, KR, McCarter, MD, The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. J Leukoc Biol 102 (2017), 381–391.
138. Ahluwalia, PK, Pandey, RK, Sehajpal, PK, Prajapati, VK, Perturbed microRNA expression by Mycobacterium tuberculosis promotes macrophage polarization leading to pro-survival foam cell. Front Immunol, 8, 2017, 107.
139. Rajaram, MV, Ni, B, Morris, JD, et al. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc Natl Acad Sci 108 (2011), 17408–17413.
140. Paladini, L, Fabris, L, Bottai, G, et al. Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res, 35, 2016, 103.
141. Dorhoi, A, Iannaccone, M, Farinacci, M, et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest 123 (2013), 4836–4848.
142. Flynn, JL, Chan, J, Triebold, KJ, et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 (1993), 2249–2254.
143. Keane, J, Gershon, S, Wise, RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001), 1098–1104.
144. Wallis, RS, van Vuuren, C, Potgieter, S, Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 48 (2009), 1429–1432.
145. Wang, Q, Wen, Z, Cao, Q, Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: a meta-analysis. Exp Ther Med 12 (2016), 1693–1704.
146. Dawson, R, Condos, R, Tse, D, et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PloS One, 4, 2009, e6984.
147. Khan, TA, Mazhar, H, Saleha, S, et al. Interferon-gamma improves macrophages function against M tuberculosis in multidrug-resistant tuberculosis patients. Chemother Res and Pract, 2016, 2016, 7295390.